NCT04939480

Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN

Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab (Tecentriq®) in Local Head and Neck Squamous Cell Carcinoma (the PIONEER Trial)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: University Hospital, Essen · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Targeting the PD-L1 pathway with atezolizumab has demonstrated objective responses across a broad range of malignancies including head and neck squamous cell carcinoma (SCCHN). MO39839 is a window of opportunity study investigating the feasibility, safety and postoperative complication rates of preoperative short time immunotherapy with atezolizumab in patients with local SCCHN. In the scope of MO39839 a comprehensive translational research program will be conducted to assess the potential effect of atezolizumab on dynamics in tumor immunity, and to identify and validate potential predictive and prognostic biomarkers.

Conditions

• Squamous Cell Carcinoma of Head and Neck

Interventions

Type	Name	Description
DRUG	Atezolizumab	Atezolizumab 1200 mg intravenous solution

Timeline

• Start date: 2021-10-06
• Primary completion: 2024-03-14
• Completion: 2024-03-14
• First posted: 2021-06-25
• Last updated: 2024-04-25

Locations

1 site across 1 country: Germany